LACK OF CHRONIC IMMUNE ACTIVATION IN HIV-INFECTED CHIMPANZEES CORRELATES WITH THE RESISTANCE OF T-CELLS TO FAS APO-1 (CD95)-INDUCED APOPTOSIS AND PRESERVATION OF A T-HELPER-1 PHENOTYPE/
Ml. Gougeon et al., LACK OF CHRONIC IMMUNE ACTIVATION IN HIV-INFECTED CHIMPANZEES CORRELATES WITH THE RESISTANCE OF T-CELLS TO FAS APO-1 (CD95)-INDUCED APOPTOSIS AND PRESERVATION OF A T-HELPER-1 PHENOTYPE/, The Journal of immunology, 158(6), 1997, pp. 2964-2976
Chimpanzees are one of the few species, along with humans, susceptible
to persistent HIV-1 infection. However, HIV-infected chimpanzees do n
ot exhibit the marked immune system alterations seen in humans and rem
ain relatively resistant to AIDS. In humans, HIV infection leads to un
responsiveness of T cells in response to TCR stimulation, associated w
ith increased T cell death by apoptosis. In an effort to understand so
me of the mechanisms used to limit lentivirus infection in African non
human primates, we compared apoptosis in infected humans vs chimpanzee
s in CD4 and CD8 T cells in relation with the expression of Bcl-2 and
Fas molecules. The intensity of apoptosis in CD4 and CD8 T cells from
infected chimpanzees was very low, was not inducible by several TCR-de
pendent activators, and was comparable to that detected in noninfected
chimpanzees. Moreover, CD45RO(+) and HLA-DR(+) subsets, which were sh
own to exhibit ex vivo a high propensity to undergo apoptosis in infec
ted humans, were not modified in infected chimpanzees. Interestingly,
in contrast to the situation found in infected humans, Fas ligation by
agonistic Abs or recombinant human Fas ligand on CD4 and CD8 T cells
from infected chimpanzees did not induce apoptosis in these subsets ev
en when Bcl-2 was down-regulated. Finally, this resistance to apoptosi
s was associated with the predominance of CD3 T cells with a Th1 pheno
type. Together these observations argue for a strong relationship amon
g the absence of chronic immune stimulation in HIV-1-infected chimpanz
ees, the normal control of lymphocyte survival, and the resistance to
disease progression.